A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
Financial Summary
| Share Statistics | IVBIY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $19,554.5 | $251.9 | 86% |
|
| Shares Out (Mil) | 244.8 | 50.8 | 80% |
|
| Institutional Ownership | 44.1% | 92.0% | 19% |
|
| Float (Mil) | 1,617.6 | 40.5 | 94% |
|
| Beta | 0.24 | 0.95 | 14% |
|
| Avg Daily Volume (000s) | 1 | 447 | 4% |
|
| Price Change (52-week) |
na | 54.2% | na |
|
| Growth | IVBIY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 14.0% | 87% |
|
| Net Income (5yr) | 22.5% | (9.8%) | 76% |
|
| EPS (5yr) | 21.0% | 16.3% | 69 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 50.3% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IVBIY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,865 | $39 | 60% |
|
| Net Income (TTM) (Mil) | $116 | ($43) | 62% |
|
| EPS (TTM) | $0.069 | ($1.600) | 42% |
|
| Operating Cash Flow (TTM) (Mil) | $1,430 | ($30) | 85% |
|
| Net Cash Flow (TTM) (Mil) | $1,144 | $3 | 95% |
|
| Long-Term Debt (Q1) (Mil) | $288 | $5 | 53% |
|
| Enterprise Value (Q1) (Mil) | $14,705 | $182 | 79% |
|
| Valuation | IVBIY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.60 | na |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IVBIY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.7% | 63.8% | 86% |
|
| Net Margin | 6.2% | (64.7%) | 52% |
|
| ROA | 2.8% | (49.7%) | 61% |
|
| ROE | 5.1% | (55.4%) | 44% |
|
| Liabilities to Assets | 48.2% | 30.3% | 40% |
|
| F-Score | na | 3 | na |
|
Innovent Biologics, Inc. did not pass any screens on 7/30/2026.
